tiprankstipranks
Blurbs

Beam Therapeutics (BEAM) Receives a Hold from J.P. Morgan

In a report released yesterday, Eric Joseph from J.P. Morgan maintained a Hold rating on Beam Therapeutics (BEAMResearch Report), with a price target of $102.00. The company’s shares closed last Monday at $33.29, close to its 52-week low of $32.90.

According to TipRanks.com, Joseph is a 1-star analyst with an average return of -6.5% and a 39.7% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Rocket Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $99.17 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $138.52 and a one-year low of $32.90. Currently, Beam Therapeutics has an average volume of 1.07M.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BEAM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Read More on BEAM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles